6538 related articles for article (PubMed ID: 3585408)
1. Identification of immunogenic B16 melanoma-associated antigens.
Johnston D; Schachne JP; Bystryn JC
J Biol Response Mod; 1987 Apr; 6(2):108-20. PubMed ID: 3585408
[TBL] [Abstract][Full Text] [Related]
2. Multiple antigens related to the major envelope glycoprotein of murine leukemia virus expressed on B16 melanoma cells as targets of host immune response.
Stackpole CW; Demsey A
Invasion Metastasis; 1984; 4(1):28-46. PubMed ID: 6329988
[TBL] [Abstract][Full Text] [Related]
3. Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice.
Falcioni R; Kennel SJ; Giacomini P; Zupi G; Sacchi A
Cancer Res; 1986 Nov; 46(11):5772-8. PubMed ID: 3756921
[TBL] [Abstract][Full Text] [Related]
4. Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma-associated antigens.
Bystryn JC
J Immunol; 1978 Jan; 120(1):96-101. PubMed ID: 627729
[TBL] [Abstract][Full Text] [Related]
5. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
[TBL] [Abstract][Full Text] [Related]
6. Immunostimulatory neem leaf preparation acts as an adjuvant to enhance the efficacy of poorly immunogenic B16 melanoma surface antigen vaccine.
Baral R; Mandal I; Chattopadhyay U
Int Immunopharmacol; 2005 Jul; 5(7-8):1343-52. PubMed ID: 15914339
[TBL] [Abstract][Full Text] [Related]
7. Identification of melanoma cell surface antigens immunogenic in mice.
Johnston D; el Rouby S; Bystryn JC
Cancer Biother; 1994; 9(1):29-38. PubMed ID: 7812355
[TBL] [Abstract][Full Text] [Related]
8. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine.
Bystryn JC; Henn M; Li J; Shroba S
Cancer Res; 1992 Nov; 52(21):5948-53. PubMed ID: 1382848
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and tumor protective activity of B16 melanoma vaccines.
Johnston D; Bystryn JC
Mol Biother; 1989; 1(4):218-22. PubMed ID: 2818873
[TBL] [Abstract][Full Text] [Related]
11. Extraction of immunogenic and suppressogenic antigens from variants of B16 melanoma exhibiting low or high metastatic potentials.
LeGrue SJ; Hearn DR
Cancer Res; 1983 Nov; 43(11):5106-11. PubMed ID: 6616449
[TBL] [Abstract][Full Text] [Related]
12. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
[TBL] [Abstract][Full Text] [Related]
13. [Immunogenicity of 2 murine B16 melanoma variants with high metastatic potential].
Hosni M; Santini R; Deschaux P; Pacheco H
C R Seances Soc Biol Fil; 1990; 184(1):47-54. PubMed ID: 2150781
[TBL] [Abstract][Full Text] [Related]
14. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
15. Syngeneic monoclonal antibodies to B16 melanoma viral antigens.
Rappaport I; Alterman AL; Braverman S; Stackpole CW
Cancer Res; 1987 Oct; 47(20):5391-6. PubMed ID: 3652042
[TBL] [Abstract][Full Text] [Related]
16. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
17. Murine melanoma-specific tumor rejection activity elicited by a purified, melanoma-associated antigen.
Hearing VJ; Gersten DM; Montague PM; Vieira WD; Galetto G; Law LW
J Immunol; 1986 Jul; 137(1):379-84. PubMed ID: 3711669
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.
Melcher A; Todryk S; Bateman A; Chong H; Lemoine NR; Vile RG
Cancer Res; 1999 Jun; 59(12):2802-5. PubMed ID: 10383135
[TBL] [Abstract][Full Text] [Related]
19. [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury].
Tan XH; Wan YH
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1596-600. PubMed ID: 16185524
[TBL] [Abstract][Full Text] [Related]
20. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]